Monalizumab, an NKG2A-blocking IgG4 mAb, has been shown to boost NK cell activation and synergistically control tumor size with limited toxicity when combined with a PD-L1 blocking mAb in Phase 2 clinical trial (156). This evidence concerns the gene CD274 and neoplasm.